Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinologyOncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology
Oncovita Won a Financing of €4,5M From Bpifrance and Raised €3,5M From Private Investors and Business Angels
Oncovita, winner of the "Innovations in biotherapies and biomanufacturing" call for projects, will benefit from €4.5 million in funding under the France 2030 investment plan, and has completed a €3.5 million round of financing from private investors to support the development of its MVdeltaC immunotherapeutic vaccine in oncology.
